Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 25, 2014 Berkshire ... is pleased to announce the release of the ... highest level of contamination containment in critical processing ... 3 and higher cleanroom environments, ValuSeal® IonX™ is ... knit laundered wiper that continues Berkshire’s innovative focus ...
(Date:10/25/2014)... -- Research and Markets has announced the ... Research Area & by End User - Global Forecast ... In this report, the global epigenetics market is ... end users. The product segments of the epigenetics market ... kits, and reagents. The subsegments of the enzymes product ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... (OTC Bulletin Board: CHBT) (,China-Biotics", "the,Company"), a leading ... and distribution of probiotics products,today announced its financial ... year, ended June 30, 2008., First ... 19.5% year-over-year to $11.4 million -- Gross ...
... ... Aug. 14 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... science of healthy aging, today announced,financial results for the quarter ... June 30, 2008 was $691,000, compared with,$471,000 reported in the ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... A custom-built, $2.5 million "split magnet" system with the potential ... made its debut at the National High Magnetic Field Laboratory ... at 25 tesla, easily besting the 17.5 tesla French record ... for early 20th-century inventor and engineer Nikola Tesla, is a ...
... as a preventative measure only achieve a short-term effect with ... up with even more aphids than untreated fields. This has ... of Wrzburg in the scientific journal PLoS One . ... triticale fields? This is what the biologists at the Department ...
... widely known PSA blood test for prostate cancer in men ... for breast cancer, the most common form of cancer in ... the ACS journal Analytical Chemistry . Chien Chou ... the test also is a potential biomarker of breast cancer ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Fewer aphids in organic crop fields 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: